Jonathan D. Buhrman, Ph.D.
Affiliations: | 2012 | Immunology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Area:
ImmunologyGoogle:
"Jonathan Buhrman"Parents
Sign in to add mentor| Jill E. Slansky | grad student | 2012 | University of Colorado, Denver | |
| (Optimizing mimotope identification and vaccine strategies to improve T cell responses against tumor antigens.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wei P, Jordan KR, Buhrman JD, et al. (2021) Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proceedings of the National Academy of Sciences of the United States of America. 118 |
| Waugh KA, Leach SM, Moore BL, et al. (2016) Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. Journal of Immunology (Baltimore, Md. : 1950) |
| Buhrman JD, Jordan KR, Munson DJ, et al. (2013) Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. The Journal of Biological Chemistry. 288: 33213-25 |
| Buhrman JD, Slansky JE. (2013) Mimotope vaccine efficacy gets a "boost" from native tumor antigens. Oncoimmunology. 2: e23492 |
| Buhrman JD, Jordan KR, U'ren L, et al. (2013) Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Research. 73: 74-85 |
| Buhrman JD, Slansky JE. (2013) Improving T cell responses to modified peptides in tumor vaccines. Immunologic Research. 55: 34-47 |
| Slansky JE, Buhrman JD. (2013) Abstract B29: Improving the identification of beneficial mimotopes using a representative tumor-specific T cell receptor. Cancer Research. 73 |
| Jordan KR, Buhrman JD, Sprague J, et al. (2012) TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunology, Immunotherapy : Cii. 61: 1627-38 |